Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG4716 DDI Study with Midazolam
NCT05030857Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OATD-01 in idiopathic pulmonary fibrosis (IPF), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration of Midazolam and Area under the plasma concentration-time curve from time zero to infinity of Midazolam. Started Sep 2021; status: completed.
02
Drugs
OATD-01
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05030857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030857.